GT Biopharma Inc.

Fact Sheet

GTBP

SYMBOL

OTCQB

GT BIOPHARMA

QUICK REFERENCE

GT Biopharma Inc.
Trading Symbol: GTBP
Outstanding Shares: 76,730,076

Website: www.GTBIOPHARMA.com

BUSINESS SUMMARY

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary Tri-specific Killer Engager (TriKE™) platform. Our TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize cancer therapies using proprietary TriKE™ technologies.

PRODUCT PIPELINE

Immunotherapy for the Treatment of Cancer
A diversified TriKE™ therapeutic pipeline targeting several oncology indications.

GTB-3550 TriKE™
GTB-3550 is the Company's first TriKE product candidate being evaluated in the clinic initially for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and human IL-15. GTB-3550 indicated for the treatment of CD33 positive leukemias such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies.

GTB-4550 TriKE™
GTB-4550 TriKE product candidate is being developed for the treatment of PD-L1+ solid tumor cancers. GTB-4550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-PDL1 antibodies and human IL-15.

GTB-5550 TriKE™
GTB-5550 TriKE product candidate is being developed for the treatment of B7H3+ solid tumor cancers. GTB-5550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-B7H3 antibodies and human IL-15.
Product Pipeline

CONTACT INFORMATION

US Headquarters
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212

Investor Relations Contact
Andrew Barwicki
516-662-9461/andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors

November 17, 2020 / GT Biopharma, Inc. is pleased to announce Mr. Bruce J. Wendel has joined the Company's Board of Directors as Vice Chairman of GT Bioscience, Inc.

Mr. Wendel served as Vice Chairman and Chief Executive Officer of Abraxis BioScience, Inc., from January 2010 to December 2010, where he oversaw the development and commercialization of Abraxane®. Mr. Wendel also led the negotiations that culminated in the acquisition of Abraxis by Celgene (CELG) in a deal valued at over $2.9 billion. Mr. Wendel retired in July 2017, and prior to retirement was Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company from July 2012 to July 2017. Prior to Abraxis, Mr. Wendel served in business and corporate development roles of increasing responsibility at American Pharmaceutical Partners, IVAX Corporation and Bristol-Myers Squibb. Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University. The Board of Directors believes that Mr. Wendel's qualifications to sit on the Board include his experience building companies and bringing oncology drugs to the market, along with his oversight of the development and commercialization of Abraxane®, and his life sciences industry experience and knowledge.

GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting

November 12, 2020 / GT Biopharma, Inc. is pleased to announce its abstract "GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts" has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition as detailed below:

Session Name: 704. Immunotherapies: Beyond T to NK
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM Eastern Time
Presentation Time: 8:00 AM Eastern Time

GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers

October 21, 2020 / GT Biopharma, Inc. is pleased to announce the publication of "NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo" in the journal Cancers, volume 12, issue 9, page 2659; (https://doi.org/10.3390/cancers12092659). The research effort was conducted by researchers at the University of Minnesota and at Massachusetts General Hospital/Harvard Medical School.

GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics

Sign $6,000,000.00 Agreement

October 6, 2020 / GT Biopharma, Inc. announced today that it had entered into a partnership agreement with Cytovance® Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink").

Under the terms of the partnership agreement, Cytovance will be the exclusive GMP manufacture for three of the Company's TriKE™ therapeutic product candidates. Cytovance will manufacture TriKE™ in accordance with GMP using Cytovance's proprietary Keystone® bacterial or mammalian expression systems. Subject to the completion of certain milestones by Cytovance, GT Biopharma has the option to pay Cytovance up to $6 million for its manufacturing services in either cash or in shares of the Company's common stock valued at the time Cytovance achieves each of several milestones over the next 12 months.

GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update

September 22, 2020 / GT Biopharma, Inc. announced today it completed treatment of the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE™ Phase I/II clinical trial.

The first patient treated with GTB-3550 at a 25mcg/kg/day dose showed a decrease in AML blast levels from 18% to 12% in the bone marrow. Additionally, we observed an increase in the patient's NK cell activity and numbers attributable to the IL-15 component of the TriKE™ molecule with no appreciable increase of a hyper-active T-cell population which could have resulted in cytokine release syndrome (CRS) or other T-cell associated toxicities. The patient experienced no adverse reactions including no constitutional symptoms such as fever, tachycardia, or chills. We also observed improvement in marrow cellularity, a decrease in AML blast levels, and improving platelet and red blood cells numbers. The patient will be retreated with an additional round of GTB-3550 therapy at the 25mcg/kg/day dose.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

GT Biopharma Inc.
Trading Symbol: GTBP

www.GTBIOPHARMA.com

Barwicki Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: